{"analyses":[{"ciLowerLimit":"9.0","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"35.8","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Treatment Difference","paramValue":"22.4"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.7","upperLimit":"27.6","value":"15.1"},{"groupId":"OG001","lowerLimit":"28.2","upperLimit":"47.5","value":"37.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"description":"The rate of conversion was calculated as the percentage of participants who were post-baseline RBC transfusion independent among participants who had an RBC transfusion within 8 weeks prior to the first dose of study drug (i.e. were transfusion dependent at Baseline). RBC transfusion independence is defined as a period of at least 56 days with no RBC transfusion after the first dose of study drug and on or before the last dose of study drug plus 30 days, or disease progression, or confirmed morphological relapse, or death, or the data cut-off date, whichever occurred earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received matching placebo to venetoclax orally once a day (QD) plus cytarabine 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.","id":"OG000","title":"Placebo + Low Dose Cytarabine (LDAC)"},{"description":"Participants received venetoclax 600 mg orally once a day plus cytarabine 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.","id":"OG001","title":"Venetoclax + Low Dose Cytarabine (LDAC)"}],"paramType":"NUMBER","populationDescription":"Full analysis set participants who were RBC transfusion-dependent at Baseline","reportingStatus":"POSTED","timeFrame":"From first dose of study drug until 30 days after last dose up to the data cut-off date of 15 February 2019; Median time on treatment was 1.7 months (range: 0.1-14.2) in the placebo arm and 3.9 months (range: 0.0-17.1) in the venetoclax arm.","title":"Percentage of Participants With RBC Transfusion Independence Among Those Who Were Transfusion Dependent at Baseline","type":"SECONDARY","unitOfMeasure":"percentage of participants"}